Pfizer Inc. (PFE)
| Market Cap | 150.33B +0.4% |
| Revenue (ttm) | 62.79B +3.9% |
| Net Income | 9.83B +131.2% |
| EPS | 1.73 +131.9% |
| Shares Out | 5.69B |
| PE Ratio | 15.32 |
| Forward PE | 9.06 |
| Dividend | $1.72 (6.51%) |
| Ex-Dividend Date | Jan 23, 2026 |
| Volume | 51,546,089 |
| Open | 26.13 |
| Previous Close | 26.10 |
| Day's Range | 25.90 - 26.47 |
| 52-Week Range | 20.92 - 27.69 |
| Beta | 0.43 |
| Analysts | Hold |
| Price Target | 27.45 (+3.82%) |
| Earnings Date | Feb 3, 2026 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for PFE stock is "Hold." The 12-month stock price target is $27.45, which is an increase of 3.82% from the latest price.
News
Pfizer: Buyer Beware, The Risk Outweighs The Reward
Pfizer: Buyer Beware, The Risk Outweighs The Reward
Pfizer: A High-Yield Pharma At A Turning Point
Pfizer remains in the 'green zone' in 2026 despite retail investors' pessimism over the approaching LOE cycle. I believe retail investors' fears about the end of exclusivity for Pfizer's blockbusters,...
US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks
The U.S. Centers for Medicare & Medicaid Services on Tuesday named a new group of branded drugs from major pharmaceutical companies including Eli Lilly , Pfizer and AbbVie for the third cycle of the M...
Pfizer vs. Merck Stock And JNJ
In the last six months Pfizer's stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and Johnson & Johnson (NYSE: JNJ) primarily due to waning demand for its COVID-19 products, a significant upcomin...
Pfizer: The Great Healthcare Plan Does Not Change My Bullish Stance
The Great Healthcare Plan has threatened the biopharma sector with mandatory global price parity, but the market is overlooking a critical carve-out specific to Pfizer. While competitors face immediat...
Pfizer: Expect Another Double Beating For Q1 (Earnings Preview)
Pfizer (PFE) remains a 'Buy' ahead of its fiscal Q1 2027 earnings, with the stock deeply discounted and consensus estimates overly pessimistic. LOE headwinds are significant but phased, while cost sav...
December Readers ID'd 9 Ideal 'Safer' Dividends In 40 Dogs
Top ten ReFa/Ro Dogs are projected to deliver 25.77%–52.74% net gains by December 2026, with an average net gain of 34.55% and risk 62% below the market. Nine of the top ten ReFa/Ro Dogs have annual d...
Pfizer CEO Albert Bourla: U.S. drug prices are coming down
Albert Bourla, CEO of Pfizer, joins 'Money Movers' to discuss drug pricing, the impact on artificial intelligence on healthcare, and more.
Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industry
Drug pricing, looming patent cliffs, dealmaking, and the first year of the second Trump administration dominated conversations at the annual JPMorgan Healthcare Conference in San Francisco. Top execu...
Novavax enters license agreement with Pfizer for vaccine development
Novavax said on Tuesday it was entering into a licensing agreement with Pfizer to develop vaccine products for infectious diseases.
Japan's Shionogi boosts ViiV stake to 21.7% as Pfizer exits
Japan's Shionogi & Co said on Tuesday it would pay $2.13 billion for new shares in joint venture ViiV Healthcare, increasing its stake in the HIV drugmaker to 21.7% as U.S. drugmaker Pfizer exits its ...
Invesco Equity And Income Fund Q4 2025 Portfolio Positioning And Performance
Ashtead has also been moving its primary listing to the New York Stock Exchange, which we believe will lift its valuation. Wells Fargo delivered strong earnings results driven by higher revenue, impro...
MoneyShow's Best Investment Ideas For 2026: Part 7
MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, an...
Pfizer: Rebound Has Just Started
Pfizer has outperformed the S&P 500 since my previous call, driven by improving fundamentals and renewed share price momentum. Positive developments around the pipeline support long-term financial sta...
Pfizer: The Most Intriguing Value Play Of 2026
Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings supporting a compelling value thesis. BRAFTOVI's Phase 3 success and PADCEV + Keyt...
Pfizer's Patent Cliff, Rising Debt, And The Fight To Stay A Buy
Pfizer remains a 'Buy' at current low valuation multiples, but faces significant headwinds from an impending patent cliff through 2030. Pfizer's top-line growth is challenged by steep declines in COVI...
Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra
Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched erectile dysfunction drug Viagra in 1998, CEO Albert Bourla said on Monday.
Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Pfizer's BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in c...
Gordian Bio Announces Research Collaboration with Pfizer to Accelerate In Vivo Target Discovery in Obesity
SAN FRANCISCO--(BUSINESS WIRE)-- #biotech--Gordian Bio Announces Research Collaboration with Pfizer to Accelerate In Vivo Target Discovery in Obesity.
Trial Date Has Been Set in MDL against Pfizer for Depo-Provera Overseen by Levin Papantonio
PENSACOLA, Fla.--(BUSINESS WIRE)--At a Case Management Conference in the Multi District Litigation against Pfizer Inc. (NYSE:PFE), the Honorable M. Casey Rodgers set a date for the first Trial, which ...
America's new vaccine doctrine for children replaces data with dogma
In just a few weeks, the U.S. went from a “quiet” recalibration of a single vaccine recommendation to a wholesale retreat from the basic architecture of childhood immunization. That shift is being sol...